Artelo Biosciences, INC 8-K filings

Artelo Biosciences held its Annual Meeting of Stockholders on July 17, 2026, where key proposals including director elections and an increase in authorized shares were approved.

Artelo Biosciences, Inc. has entered into an At The Market Offering Agreement to sell up to $6.53 million of its common stock through H.C. Wainwright & Co., LLC.

Artelo Biosciences has successfully met Nasdaq's minimum stockholders' equity and annual meeting requirements, ending a period of potential delisting risk.

Artelo Biosciences announced a $300,000 financing deal and a strategic expansion of its ART27.13 program to address muscle loss in GLP-1 therapy patients, supported by preclinical data and a new patent filing.

Artelo Biosciences, a clinical-stage biopharmaceutical company, reported a significant increase in net loss and a net capital deficiency for 2025, raising substantial doubt about its ability to continue as a going concern.

Artelo Biosciences will implement a 1-for-3 reverse stock split to enhance marketability and liquidity, effective March 10, 2026.

Artelo Biosciences, Inc. has entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC for up to $50 million in common stock.

Artelo Biosciences, Inc. received an extension from Nasdaq to regain compliance with its stockholders' equity requirement by March 30, 2026, while having cured its annual meeting deficiency.

ARTELO BIOSCIENCES, INC. announced the results of its reconvened Annual Meeting of Stockholders, including the re-election of two Class II directors and the approval of executive compensation.

Artelo Biosciences received a Nasdaq notice of non-compliance for failing to hold its annual meeting, adding to existing delisting concerns over minimum stockholders' equity.

Artelo Biosciences, Inc. adjourned its 2025 annual meeting due to insufficient quorum and will reconvene on January 30, 2026, with an added proposal to ratify its independent auditor.

Artelo Biosciences received a delist determination from Nasdaq due to non-compliance with minimum stockholders' equity, but plans to appeal.

Artelo Biosciences, Inc. has amended its bylaws to remove stockholders' right to fill Board vacancies and establish plurality voting for director elections.

Artelo Biosciences, Inc. has completed a private placement of $690,154.69 in convertible notes and warrants to purchase 438,182 shares, including participation from company directors and officers.

Artelo Biosciences, Inc. announced the appointment of Mark Spring as its new Chief Financial Officer and Treasurer, effective November 1, 2025, while also significantly amending CEO Gregory Gorgas's employment agreement to enhance severance benefits.

Artelo Biosciences, Inc. has entered into a cooperation agreement with Daniel S. Farb and his affiliates, resolving a potential proxy contest and establishing a standstill period.

Artelo Biosciences, a clinical-stage pharmaceutical company, successfully closed an underwritten public offering raising approximately $2.0 million in gross proceeds through the sale of common stock and pre-funded warrants.

Artelo Biosciences, Inc. announced the partial exercise of an over-allotment option, generating approximately $0.25 million in additional gross proceeds from its recent underwritten offering.

Artelo Biosciences, Inc. announced amendments to its bylaws, including the elimination of stockholder action without a meeting and changes to board meeting notice periods.

Artelo Biosciences successfully closed an underwritten public offering, raising approximately $3 million to fund clinical development and operations.

Artelo Biosciences announced positive interim Phase 2 results for ART27.13 in cancer anorexia-cachexia syndrome, showing significant weight and lean body mass gains.

ARTELO BIOSCIENCES, INC. stockholders approved an increase in authorized common stock but rejected an increase in authorized preferred stock at a Special Meeting.

Artelo Biosciences, Inc. terminated a private placement agreement and a consulting agreement, citing unmet closing conditions and mutual consent, respectively.

Artelo Biosciences entered a four-year consulting agreement with ABK Labs, issuing warrants for 55,000 shares to bolster its digital asset strategy and business development.

Artelo Biosciences announced a $9.475 million private placement to fund a new Solana-centric digital asset treasury strategy, becoming the first publicly-traded pharmaceutical company to adopt SOL as a core reserve asset, alongside positive UK regulatory guidance for its ART12.11 clinical program.

Artelo Biosciences, Inc. has established an At-The-Market Offering Agreement to sell up to $6.5 million of its common stock, providing a flexible mechanism for future capital raises.

Artelo Biosciences, a clinical-stage biopharmaceutical company, has reported preliminary financial estimates indicating negative working capital and ongoing substantial doubt about its ability to continue as a going concern, despite recent capital raising activities and a 1-for-6 reverse stock split.

Artelo Biosciences, a clinical-stage pharmaceutical company, announced a private placement raising $1.425 million, with plans to allocate a portion to digital currency and the remainder for clinical trials and working capital.

Artelo Biosciences, Inc. has successfully completed a 1-for-6 reverse stock split, effective June 13, 2025, which enabled the company to regain compliance with Nasdaq's minimum bid price requirement.

Artelo Biosciences, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement, potentially jeopardizing its continued listing.